Drugs

, Volume 51, Issue 3, pp 367–382 | Cite as

Long Term Treatment of Bipolar Disorder

  • Trevor Silverstone
  • Sarah Romans
Disease Management

Summary

Bipolar disorder is characterised by recurrent episodes of mania and depression. The major objective of long term treatment is to reduce the frequency of these episodes. Lithium is the most widely recommended drug for this purpose, having been shown in controlled clinical trials to be more effective than placebo in reducing the likelihood of relapse. Unfortunately, its effectiveness in clinical practice is less than that predicted from these trials. A major cause of relapse is noncompliance, largely due to intolerance to adverse effects such as perceived mental sluggishness, thirst, polyuria and weight gain. Regular monitoring of lithium plasma concentrations is required to ensure that the range of 0.5 to 0.9 mmol/L is not exceeded. Concentrations above this can lead to toxic symptoms, which if unchecked can cause brain damage and even death.

The anticonvulsant drugs carbamazepine and valproic acid (sodium valproate) are potential alternatives to lithium. Patients who relapse frequently despite lithium may benefit from the addition of one of these agents, although formal clinical trial evidence of the efficacy of such combination treatment is lacking. Antipsychotics, administered as a depot formulation, can reduce the likelihood of relapse in patients with frequent manic episodes, especially if associated with poor compliance. Psychological treatment and patient education have been shown to improve outcome, and should be made more widely available to all patients with bipolar disorder.

Keywords

Lithium Bipolar Disorder Carbamazepine Valproate Bipolar Patient 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Psychiatric Association. Diagnostic and Statistical Manual: DSM-IV. 4th ed. Washington (DC): American Psychiatric Press, 1994Google Scholar
  2. 2.
    World Health Organization. The ICD-10 Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 1st ed. Geneva: WHO, 1992: 362Google Scholar
  3. 3.
    Akiskal HS, Cassano GB, Musetti L, et al. Psychopathology, temperament, and past course in major depressions: I. Review of evidence for bipolar spectrum. Psychopathology 1989; 22: 268–77PubMedGoogle Scholar
  4. 4.
    Silverstone T, Romans-Clarkson SE. Bipolar affective disorder: the causes and prevention of relapse. Br J Psychiatry 1989; 154: 321–35PubMedGoogle Scholar
  5. 5.
    Goodwin FK, Jamison KR. Manic-depressive illness. 1st ed. New York (NY): Oxford University Press, 1990Google Scholar
  6. 6.
    Prien RF, Potter WZ. NIMH workshop report on treatment of bipolar disorder. Psychopharmacol Bull 1990; 26: 409–27PubMedGoogle Scholar
  7. 7.
    Zarin DA, Pass TM. Lithium and the single episode: when to begin long-term prophylaxis for bipolar disorder. Med Care 1987; 25: S76–84PubMedGoogle Scholar
  8. 8.
    Mander AJ. Is lithium justified after one manic episode? Acta Psychiatr Scand 1986; 73: 60–7PubMedGoogle Scholar
  9. 9.
    Cade J. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 36: 349–52Google Scholar
  10. 10.
    Baastrup PC, Schou M. Lithium as a prophylactic agent: its effect against recurrent depression and manic-depressive psychosis. Arch Gen Psychiatry 1967; 16: 162–72PubMedGoogle Scholar
  11. 11.
    Blackwell B, Shepherd M. Prophylactic lithium: another therapeutic myth? Lancet 1968; 1: 968–71PubMedGoogle Scholar
  12. 12.
    Baastrup PC, Poulson JC, Schou M, et al. Prophylactic lithium: double-blind discontinuation in manic-depressive and recurrent depressive disorders. Lancet 1970; 2: 326–30PubMedGoogle Scholar
  13. 13.
    Coppen A Noguera R, Bailey J, et al. Prophylactic lithium in affective disorders. Lancet 1971; 2: 275–9PubMedGoogle Scholar
  14. 14.
    Prien R, Caffey E, Klett J. Prophylactic efficacy of lithium carbonate in manic-depressive illness. Arch Gen Psychiatry 1973; 28: 337–41PubMedGoogle Scholar
  15. 15.
    Moncrief J. Lithium revisited: a re-examination of the placebocontrolled trials of lithium prophylaxis in manic-depressive disorder. Br J Psychiatry 1995; 167: 569–74Google Scholar
  16. 16.
    Symonds RL, Williams P. Lithium and the changing incidence of mania. Psychol Med 1981; 11: 193–6PubMedGoogle Scholar
  17. 17.
    Dickson WE, Kendell RE. Does maintenance lithium therapy revent recurrences of mania under ordinary clinical conditions? Psychol Med 1986; 16: 521–30PubMedGoogle Scholar
  18. 18.
    Harrow MGJF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71PubMedGoogle Scholar
  19. 19.
    Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilising survival analysis. Arch Gen Psychiatry 1990; 47: 1106–11PubMedGoogle Scholar
  20. 20.
    Winokur G, Coryell W, Keller M, et al. A prospective follow-up of patients with bipolar and primary unipolar affective disorder. Arch Gen Psychiatry 1993 Jun; 50: 457–65PubMedGoogle Scholar
  21. 21.
    Dunner DL Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229–33PubMedGoogle Scholar
  22. 22.
    Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989; 98: 535–8PubMedGoogle Scholar
  23. 23.
    Maj M, Arena F, Lovero N, et al. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder. Pharmacopsychiatry 1985; 18: 309–13PubMedGoogle Scholar
  24. 24.
    Abou-Saleh MT. Who reponds to prophylactic lithium therapy? Br J Psychiatry 1993; 163 Suppl. 21: 20–6Google Scholar
  25. 25.
    Reiger DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area (ECA) studies. JAMA 1990; 264: 2511–8Google Scholar
  26. 26.
    Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness and efficience. Br J Psychiatry 1994; 164: 741–6PubMedGoogle Scholar
  27. 27.
    Mitchell PB, Parker GB. Treatment of bipolar disorder. Med J Aust 1991; 155: 488–93PubMedGoogle Scholar
  28. 28.
    American Psychiatry Association Practice Guidelines. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151 Suppl. 1–36Google Scholar
  29. 29.
    Suppes T, Baldessarini RJ, Faedda GL. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082–8PubMedGoogle Scholar
  30. 30.
    Post RM, Leverich GS, Altshuler L, et al. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992; 149: 1727–9PubMedGoogle Scholar
  31. 31.
    Jerram TC, McDonald R. Plasma lithium control with particular reference to minimum effective levels. In: Johnson FN, Johnson S, editors. Lithium in medical practice, Lancaster: MTP Press, 1978: 407–13Google Scholar
  32. 32.
    Sashidharan SP, McGuire RJ, Glen AIM. Plasma lithium levels and therapeutic outcome in the prophylaxis of affective disorders: a retrospective study. Br J Psychiatry 1982; 140: 619–22PubMedGoogle Scholar
  33. 33.
    Gelenberg AJ, Kane JM, Keller MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–93PubMedGoogle Scholar
  34. 34.
    Sachs G, Renshaw P, Lafer B, et al. Variability of brain lithium levels during maintenance treatment: a magnetic resonance spectroscopy study. Biol Psychiatry 1995; 38: 422–8PubMedGoogle Scholar
  35. 35.
    Shelley RK, Silverstone T. Single dose pharmacokinetics of 5 formulations of lithium: a controlled comparison in healthy subjects. Int Clin Psychopharmacol 1986; 1: 324–31PubMedGoogle Scholar
  36. 36.
    Bennie EH, Chalmers R. Serum concentrations of lithium after three proprietary preparations of lithium carbonate. In: Johnson FN, Johnson S, editors. Lithium in medical practice. Lancaster: MTP Press, 1978: 381–5Google Scholar
  37. 37.
    Muir A, Davidson R, Silverstone T, et al. Two regimes of lithium prophylaxis and renal function. Acta Psychiatr Scand 1989; 80: 579–83PubMedGoogle Scholar
  38. 38.
    Peet M, Pratt JP. Lithium: current status in psychiatric disorders. Drugs 1993; 46: 7–17PubMedGoogle Scholar
  39. 39.
    Jamison KGRH, Goodwin FK. Patient and physician attitudes toward lithium: relationship to compliance. Arch Gen Psychiatry 1979; 36: 866–9PubMedGoogle Scholar
  40. 40.
    Schou M. Effects of long-term lithium treatment on kidney function: an overview. J Psychiatr Res 1988; 22: 287–96PubMedGoogle Scholar
  41. 41.
    Schou M. Lithium prophylaxis: myths and realities. Am J Psychiatry 1989; 146: 573–6PubMedGoogle Scholar
  42. 42.
    Schou M, Vestergaard P. Prospective studies on a lithium cohort: 2. Renal function: water and electrolyte metabolism. Acta Psychiatr Scand 1988; 78: 427–33PubMedGoogle Scholar
  43. 43.
    Lazarus JH. Endocrine and metabolic effects of lithium. New York (NY): Plenum Publishing, 1986Google Scholar
  44. 44.
    Chen Y. Lithium and weight gain. Int Clin Pharmacol 1990; 6: 217–25Google Scholar
  45. 45.
    Zalzstein E, Koren G, Einarson T, et al. A case-control study on the association between first trimester exposure to lithium and Ebsteins’s anomaly. Am J Cardiol 1990; 65: 817–8PubMedGoogle Scholar
  46. 46.
    Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146–50PubMedGoogle Scholar
  47. 47.
    Jacobson S, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during the first trimester. Lancet 1992; 339: 530–3PubMedGoogle Scholar
  48. 48.
    Stewart DE, Klompenhouwer JL, Kendell RE, et al. Prophylactic lithium in puerperal psychosis: the experience of three centres. Br J Psychiatry 1991; 158: 393–7PubMedGoogle Scholar
  49. 49.
    Austin M-PV. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry 1992; 161: 692–4PubMedGoogle Scholar
  50. 50.
    Jamison KR, Akiskal HS. Medication compliance in patients with bipolar disorder. Psychiatr Clin North Am 1983; 6: 175–92PubMedGoogle Scholar
  51. 51.
    Aagaard J, Vestergaard P. Predictors of outcome in prophylactic lithium treatment: a 2-year prospective study. J Affect Disord 1990; 18: 259–66PubMedGoogle Scholar
  52. 52.
    Goodwin G. Recurrence of mania after lithium withdrawal. Br J Psychiatry 1994; 164: 149–52PubMedGoogle Scholar
  53. 53.
    Mander AJ, Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; 2: 15–7PubMedGoogle Scholar
  54. 54.
    Mander AJ. Is there a lithium withdrawal syndrome? Br J Psychiatry 1986; 149: 498–501PubMedGoogle Scholar
  55. 55.
    Faedda GL, Tondo L, Baldessarini R, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448–55PubMedGoogle Scholar
  56. 56.
    Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140_(12): 1602–4Google Scholar
  57. 57.
    Kishimoto A, Ogura C, Hazama H, et al. Long-term prophylactic effects of carbamazepine in affective disorder. Br J Psychiatry 1983; 143: 327–31PubMedGoogle Scholar
  58. 58.
    Placidi GF, Lenzi A, Lazzerini F, et al. The comparative efficacy and safety of carbamazepine versus lithium: a randomized double-blind 3-year trial in 83 patients. J Clin Psychiatry 1986; 47: 490–4PubMedGoogle Scholar
  59. 59.
    Lusznat RM, Murphy DP, Nunn CM. Carbamzepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153: 198–204PubMedGoogle Scholar
  60. 60.
    Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar disorder. Acta Psychiatr Scand 1992; 85: 114–8PubMedGoogle Scholar
  61. 61.
    Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28: 221–31PubMedGoogle Scholar
  62. 62.
    Watkins SE, Callender K, Thomas DR, et al. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 1987; 150: 180–2PubMedGoogle Scholar
  63. 63.
    Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995 Mar; 166: 378–81PubMedGoogle Scholar
  64. 64.
    Joyce PR. Carbamazepine in rapid cycling bipolar disorder. Int Clin Psychopharmacol 1988; 3: 123–9PubMedGoogle Scholar
  65. 65.
    Post RM, Leverich GS, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318–27PubMedGoogle Scholar
  66. 66.
    Post RM. Anticonvulsants and novel drugs. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1992: 387–417Google Scholar
  67. 67.
    Tohen M, Castillo J, Baldesserini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2, 228 patients at risk. Am J Psychiatry 1995; 152: 413–8PubMedGoogle Scholar
  68. 68.
    Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine: part I. J Clin Psychopharmacol 1991; 11: 198–203PubMedGoogle Scholar
  69. 69.
    Roy-Byrne PP, Joffe RT, Uhde TW, et al. Carbamazepine and thyroid function in affectively ill patients. Arch Gen Psychiatry 1984; 41: 1150–3PubMedGoogle Scholar
  70. 70.
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7PubMedGoogle Scholar
  71. 71.
    Emrich HM, Zerssen Dv, Kissling W, et al. Therapeutic effect of valproate in mania. Am J Psychiatry 1981; 138: 256PubMedGoogle Scholar
  72. 72.
    Pope HG, McElroy SL, Keck PE, et al. Valproate in the treatment of acute mania. Arch Gen Psychiatry 1991; 48: 62–8PubMedGoogle Scholar
  73. 73.
    Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149: 108–11PubMedGoogle Scholar
  74. 74.
    Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271: 918–24PubMedGoogle Scholar
  75. 75.
    McElroy SL, Keck PE, Pope HG, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12: 42S–52SPubMedGoogle Scholar
  76. 76.
    Hayes SG. Long-term valproate prophylaxis in refractory affective disorder. Ann Clin Psychiatry 1992; 4: 55–63Google Scholar
  77. 77.
    Calabrese JR, Delucchi G. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990; 147: 431–4PubMedGoogle Scholar
  78. 78.
    McElroy SL, Keck PE, Pope HG, et al. Valproate in the treatment of rapid-cycling bipolar disorder. J Clin Psychopharmacol 1988; 8: 275–9PubMedGoogle Scholar
  79. 79.
    Mitchell P, Withers K, Jacobs G, et al. Combining lithium and sodium valproate for bipolar disorder. Aust NZ J Psychiatry 1994; 28: 141–3Google Scholar
  80. 80.
    Thisted E, Ebbesen F. Malformations, withdrawal manifestations and hypoglycaemia after exposure to valproate in utero. Arch Dis Child 1993; 69: 288–91PubMedGoogle Scholar
  81. 81.
    Naylor G, Scott C. Depot injections for affective disorders. Br J Psychiatry 1980; 136: 105PubMedGoogle Scholar
  82. 82.
    Lowe M, Batchelor D. Depot neuroleptics and manic depressive psychosis. Int Clin Psychopharmacol 1986; 1 Suppl. 1: 53–62PubMedGoogle Scholar
  83. 83.
    Ahlfors UG, Baastrup PC, Denker SJ, et al. Flupenthixol decoanate in recurrent manic depressive illness: a comparison with lithium. Acta Psychiatr Scand 1981; 64: 226–37PubMedGoogle Scholar
  84. 84.
    Esparon J, Kalloor J, Naylor G, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithiumtreated manic depressive patients. Br J Psychiatry 1986; 148: 723–5PubMedGoogle Scholar
  85. 85.
    White E, Cheung P, Silverstone T. Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8: 119–22PubMedGoogle Scholar
  86. 86.
    Littlejohn R, Leslie F, Cookson J. Depot antipsychotics in the prophylaxis of bipolar disorder. Br J Psychiatry 1994; 165: 827–9PubMedGoogle Scholar
  87. 87.
    Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder. Int Clin Psychopharmacol 1990; 6: 45–50Google Scholar
  88. 88.
    Banov MD, Zarate C, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994; 55: 295–300PubMedGoogle Scholar
  89. 89.
    Zarate CA, Tohen M, Banov MD, et al. Is clozapine a mood stabiliser? J Clin Psychiatry 1995; 56: 108–12PubMedGoogle Scholar
  90. 90.
    Wehr TA, Goodwin FK. Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 1987; 144: 1403–11PubMedGoogle Scholar
  91. 91.
    Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Arch Gen Psychiatry 1984; 41: 1096–104PubMedGoogle Scholar
  92. 92.
    Peet M. Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. Br J Psychiatry 1994; 164: 549–50PubMedGoogle Scholar
  93. 93.
    Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391–3PubMedGoogle Scholar
  94. 94.
    Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145: 179–84PubMedGoogle Scholar
  95. 95.
    Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder; demographics, diagnosis, family history and course. Arch Gen Psychiatry 1992; 49_(2): 126–31Google Scholar
  96. 96.
    Johnstone EC, Owens DGC, Lambert MT, et al. Combination tricyclic antidepressant and lithium maintenance in unipolar and bipolar depressed patients. J Affect Disord 1990; 20: 225–33PubMedGoogle Scholar
  97. 97.
    Bauer MS, Calabrese J, Dunner DL, et al. Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Am J Psychiatry 1994; 151: 506–15PubMedGoogle Scholar
  98. 98.
    Maj M, Magliano L, Pirozzi R, et al. Validity of rapid cycling as a course specifier for bipolar disorder. Am J Psychiatry 1994; 151: 1015–9PubMedGoogle Scholar
  99. 99.
    Peet M, Harvey NS. Lithium maintenance: 1. A standard education programme for patients. Br J Psychiatry 1991; 158: 197–200PubMedGoogle Scholar
  100. 100.
    Harvey NS, Peet M Lithium maintenance: 2. Effects of personality on health information acquisition and compliance. Br J Psychiatry 1991; 158: 200–4PubMedGoogle Scholar
  101. 101.
    Wehr TA, Sack DA, Rosenthal NE. Sleep reduction as a final common pathway in the genesis of mania. Am J Psychiatry 1987; 144: 201–4PubMedGoogle Scholar
  102. 102.
    Eyers K, Brodaty H, Roy K, et al. Patient satisfaction with a mood disorders unit: elements and components. Aust NZ J Psychiatry 1994; 28: 279–87Google Scholar
  103. 103.
    Kehoe RF, Mander AJ. Lithium treatment: prescribing and monitoring habits in hospital and general practice. BMJ 1992; 304: 552–4PubMedGoogle Scholar
  104. 104.
    Scott J. Psychotherapy for bipolar disorder. Br J Psychiatry 1995; 167: 581–8PubMedGoogle Scholar
  105. 105.
    Romans SE, McPherson HM. The social networks of bipolar affective disorder patients. J Affective Disord 1992; 25: 221–8Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Trevor Silverstone
    • 1
  • Sarah Romans
    • 1
  1. 1.Department of Psychological Medicine, Dunedin Medical SchoolUniversity of OtagoDunedinNew Zealand

Personalised recommendations